What is LGND's P/E ratio?

Ligand Pharmaceuticals Incorporated (LGND) currently trades at a P/E ratio of 34.53.

Ligand Pharmaceuticals Incorporated reports a Return on Equity (ROE) of 15.40%.

What is LGND's dividend yield?

Ligand Pharmaceuticals Incorporated offers a dividend yield of 0.00%.

What is LGND's Quality Score?

Our AI rates LGND's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LGND?

Our AI Timing Score for LGND is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LGND belong to?

Ligand Pharmaceuticals Incorporated is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Ligand Pharmaceuticals Incorporated (LGND) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

LGND AI Analysis Summary

Our AI summary for LGND: Ligand Pharmaceuticals Incorporated (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 34.53, ROE of 15.40%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LGND

Ligand Pharmaceuticals Incorporated

US:NASDAQ STOCK Healthcare >> Biotechnology News 90

USD 292.04

4.50 (1.56%) Day Change

Watchlist Portfolio Compare Chart

34.53

P/E

0.45

D/E

15.4%

ROE

10.0%

ROA

0.00%

Div Yield

-0.03

PEG

LIGAND PHARMACEUTICALS INCORPORATED
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 292.04 Price 4.50 (1.56%) Day Change	NEWS SCORE: 90

LGND, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is good , ...

Quality Factors

47%

In Recommendations?	In "Invest - GROWTH" Section
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	90
Magic Formula Rank by ROA	1619
Magic Formula Rank by ROE	1619
Magic Formula Rank by ROIC	1558
Price	292.04
PBV / Sector	5.78 / 44,219.29
Earning Per Share	7.78

PE / Sector	34.53 / 19.28
PEG or PE/Growth / Sector	-0.03 / 1.23
Average 1M Daily Value	90.24 M
Average 1W Daily Value	76.83 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	55.95 / 98.22 GREAT
NPM Average (%) / Sector	24.53 / -1,697.63 GREAT
NPM Change Average (%) / Sector	-610.87 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	10.02 / 185,260.96
ROA Average (%) / Sector	3.96 / 36,684.70
ROA Change Average (%) / Sector	-573.72 / 422,221.66
ROE (%) / Sector	15.40 / 243,762.23
ROE Average (%) / Sector	5.80 / 48,758.47
ROE Change Average (%) / Sector	-733.46 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:47
Symbol	LGND
Name	LIGAND PHARMACEUTICALS INCORPORATED
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	20.04 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,762.61 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 555 Heritage Drive, Jupiter, FL, United States, 33458

Phone: 858 550 7500

Website: https://www.ligand.com

Sector: Healthcare >> Biotechnology

Description: Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.